Elpiscience Biopharma

[Available On-Demand]
Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Its most advanced assets, ES101, ES102 and ES104 are both in Phase I clinical stage, and three in-house developed candidates with first-in-class potential are currently being evaluated in IND-enabling studies. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by top investors such as Lilly Asia Ventures, Hillhouse Capital and CDH Investment.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
ES101, ES012, ES104
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
>5
Speaker
photo
CEO
Elpiscience Biopharma